ReviewMovement disorders : official journal of the Movement Disorder Society2013
Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline.
Review in Movement disorders : official journal of the Movement Disorder Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 60 citations in OpenAlex.
- Deep brain stimulation of the internal pallidum in Huntington's disease patients: clinical outcome and neuronal firing patterns.Journal of neurology · 2016Trial
- Update on the Symptomatic Treatment of Huntington's Disease: From Pathophysiology to Clinical Practice.International journal of molecular sciences · 2025Review
- Longitudinal Treatment Patterns of Chorea in North American Patients with Huntington's Disease: Data from Enroll-HD.Neurology and therapy · 2025Article
- Split syndrome with acute-onset hemichorea and contralateral progressive parkinsonism: a case report.Acta neurologica Belgica · 2025Article
- Real-world safety analysis of deutetrabenazine post-marketing: a disproportionality study leveraging the FDA Adverse Event Reporting System (FAERS) database.BMC pharmacology & toxicology · 2025Article
- A Practical Guide for Diagnostic Investigations and Special Considerations in Patients With Huntington's Disease in Korea.Journal of movement disorders · 2025Article
- Medication Use and Treatment Indications in Huntington's Disease; Analyses from a Large Cohort.Movement disorders clinical practice · 2024Observational
- Evidence-Based Review on Symptomatic Management of Huntington's Disease.Journal of movement disorders · 2024Article
- Computational insights into missense mutations in HTT gene causing Huntington's disease and its interactome networks.Irish journal of medical science · 2023Article
- Use of Objective Outcomes Measures to Verify the Effects of ICF-Based Gait Treatment in Huntington's Disease Patient on Globus Pallidus Deep Brain Stimulation: A Case Report.Frontiers in rehabilitation sciences · 2022Article
- Comparing Risperidone and Olanzapine to Tetrabenazine for the Management of Chorea in Huntington Disease: An Analysis from the Enroll-HD Database.Movement disorders clinical practice · 2019Article
- Understanding How Chorea Affects Health-Related Quality of Life in Huntington Disease: An Online Survey of Patients and Caregivers in the United States.The patient · 2018Article
- Clinical Management of Neuropsychiatric Symptoms of Huntington Disease: Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep Disorders.Journal of Huntington's disease · 2018Article
- Review
- Review
- Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.Journal of cellular and molecular medicine · 2015Article
- Clinical diagnosis and management in early Huntington's disease: a review.Degenerative neurological and neuromuscular disease · 2015Review
- Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.Drug design, development and therapy · 2015Article
- Diagnosis and treatment of chorea syndromes.Current neurology and neuroscience reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, the American Academy of Neurology published an evidence-based guideline for the pharmacological treatment of chorea in Huntington's disease. Although the progress in medical care because of the implementation of criteria of evidence-based medicine is undisputed, the guideline classifies the level of evidence for drugs to reduce chorea based on anchors in the Unified Huntington's Disease Rating Scale-Total Motor Score chorea sum score, which were chosen arbitrarily and do not reflect validated or generally accepted levels of clinical relevance. Thus, the guideline faces several serious limitations and delivers clinical recommendations that do not represent current clinical practice; these are reviewed in detail, and arguments are presented why these recommendations should not be followed. To remedy the lack of evidence-based recommendations and provide guidance to a pragmatic symptomatic therapy of chorea in HD, a flow-chart pathway that follows currently established clinical standards based on expert opinion is presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.